Atezolizumab for treating metastatic colorectal cancer after 2 therapies [ID1298]
Discontinued
Reference number: GID-TA10228
The National Institute for Health and Care Excellence has been asked to conduct an appraisal of atezolizumab for treating locally advanced or metastatic colorectal cancer after 2 therapies We have recently invited stakeholders to respond to a written consultation on the draft scope for this topic. The company that market atezolizumab have shared confidential information with NICE, in light of this information NICE will not be progressing with the scoping exercise. Consequently the consultation on the draft scope will stop.
If you have any comments or concerns please contact the project manager for this proposed appraisal Michelle Adhemar via email on michelle.adhemar@nice.org.uk